146 related articles for article (PubMed ID: 36493736)
1. Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis.
Tayubi IA; Madar IH
Comput Biol Med; 2023 Jan; 152():106377. PubMed ID: 36493736
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
3. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
4. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
5. Association analysis between the interaction of RAS family genes mutations and papillary thyroid carcinoma in the Han Chinese population.
Jin M; Li Z; Sun Y; Zhang M; Chen X; Zhao H; Yu Q
Int J Med Sci; 2021; 18(2):441-447. PubMed ID: 33390813
[TBL] [Abstract][Full Text] [Related]
6. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid.
Myers MB; McKim KL; Parsons BL
Mol Carcinog; 2014 Feb; 53(2):159-67. PubMed ID: 22930660
[TBL] [Abstract][Full Text] [Related]
7. Single thyroid tumour showing multiple differentiated morphological patterns and intramorphological molecular genetic heterogeneity.
Schopper HK; Stence A; Ma D; Pagedar NA; Robinson RA
J Clin Pathol; 2017 Feb; 70(2):116-119. PubMed ID: 27387987
[TBL] [Abstract][Full Text] [Related]
8. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
11. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
12. High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia.
Heriyanto DS; Laiman V; Limantara NV; Anantawikrama WP; Yuliani FS; Cempaka R; Anwar SL
BMC Res Notes; 2022 Dec; 15(1):369. PubMed ID: 36510281
[TBL] [Abstract][Full Text] [Related]
13. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
14.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.
Paulson VA; Shivdasani P; Angell TE; Cibas ES; Krane JF; Lindeman NI; Alexander EK; Barletta JA
Thyroid; 2017 Apr; 27(4):506-511. PubMed ID: 28114855
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
17. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract][Full Text] [Related]
18. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
19. Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
Tan A; Stewart CJ; Garrett KL; Rye M; Cohen PA
Endocr Pathol; 2015 Dec; 26(4):296-301. PubMed ID: 26362194
[TBL] [Abstract][Full Text] [Related]
20. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
